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Purpose: To evaluate vasomotor symptoms and soy and hormone therapy use in women who 
had previously participated in the Soy Estrogen Alternative (SEA) study, a trial conducted to 
compare the effects of soy protein supplements containing differing levels of isoflavones on 
menopausal symptoms, chronic disease risk factors, and health-related quality of life in peri-
menopausal and postmenopausal women.
Participants and methods: Two years after the SEA study ended participants were recontacted 
to complete questionnaires to quantify their health status, medications, menopausal symptoms, 
and their use of hormone therapy and soy-based foods and supplements. Participants were also 
asked to record vasomotor symptoms for seven days.
Results: Surveys were collected from 182 of the 241 participants who had been enrolled in the 
SEA study (76% response rate). Women were 55 ± 2.8 years of age, well educated (80% more 
than high school), and 93% reported good to excellent health. All but six reported experienc-
ing at least one menopausal symptom, and 56% reported one or more hot flashes on one or 
more days. Eighty-one women (45%) continued to use soy for menopausal symptom relief, and 
58 (32%) were using hormone therapy. Women taking hormone therapy were experiencing fewer 
and less severe hot flashes than those who were not taking hormone therapy (P , 0.001); hot 
flash frequency and severity did not differ significantly between those who did and did not use 
soy, after controlling for hormone therapy use.
Conclusion: Most participants reported they were still experiencing menopausal symptoms. 
Additionally, half of the most symptomatic women (not taking hormone therapy) were still 
consuming soy products for vasomotor symptoms.
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Introduction
It has been reported that 75% of menopausal women experience vasomotor symptoms 
and that these symptoms can markedly impact quality of life.1,2 Complementary and 
alternative medicine use is high in women seeking relief from the vasomotor symptoms 
of menopause. Soy consumption to treat menopausal symptoms has been studied as a 
result of cross-cultural comparisons showing that women who live in countries where 
substantial amounts of soy are consumed (ie, Japan and the Pacific Rim) not only have 
lower rates of coronary heart disease, fractures, and uterine or breast cancer, but also 
report fewer menopausal symptoms than women who live in countries where people 
consume very little soy in their diet (ie, the US and Western Europe).3–5
The Soy Estrogen Alternative (SEA) study was conducted to compare the effects 
of soy protein supplements containing differing levels of isoflavones (plant phytoe-
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  quality of life in perimenopausal and postmenopausal 
women. The women who participated in the SEA study were 
seeking vasomotor symptom relief and, although eligible for 
hormone therapy, did not want to use it.
The purpose of this paper is to report the results of a 
follow-up survey that was sent to the SEA participants two 
or more years following their closeout visit for the SEA 
study. We describe their self-reported vasomotor and other 
menopausal symptoms in relationship to hormone therapy 
use and soy consumption.
Materials and methods
soy estrogen Alternative study
The SEA study was a double-blind randomized study to com-
pare the effects of dietary supplements containing differing 
levels of isoflavones on menopausal symptoms, chronic dis-
ease risk, and health-related quality of life in perimenopausal 
and menopausal women. To be eligible for the SEA study, 
women had to be 45–55 years old, have had no more than one 
menstrual period three months prior to enrollment, be healthy, 
have at least one vasomotor symptom in a 24-hour period, 
and not be using traditional hormone replacement therapy or 
willing to discontinue use (three-month washout). A total of 
241 participants were enrolled. The SEA study investigators 
reported that there was a significant reduction in the number 
and severity of symptoms during the 24-month follow-up 
period in all SEA treatment groups (P , 0.001). However, 
there were no significant differences at 24 months between 
the three groups (P = 0.10). A complete report of the study 
methodology and results are published elsewhere.6
Follow-up survey
Two or more years after their final (24-month) SEA study 
visit, a survey questionnaire was sent to all 241 participants. 
The survey contained questions about current health and 
reproductive status, prescription medications, menopausal 
symptoms, and use of soy products. Participants were asked 
about the use of soy foods (yes/no), soy/isoflavone pills 
(yes/no), and herbal products (yes/no) for the treatment of 
hot flashes. Careful attention was paid to limit participant 
burden, and the questionnaire was pretested prior to sending 
it to the study participants.
recontacting participants
Participants were sent a cover letter explaining the study, an 
informed consent form, and the self-administered survey 
questionnaire. The women were asked to return the completed 
survey questionnaire and signed consent in the stamped, 
addressed envelope enclosed. Women were sent a reminder 
postcard two weeks after the survey questionnaires were 
sent out, and, at four weeks, nonresponders were contacted 
by telephone. The research was in compliance with the 
  Helsinki Declaration, and the Wake Forest University School 
of Medicine Institutional Review Board approved the study 
and all study materials.
statistical analysis
Participants were asked to record hot flash symptoms over 
a seven-day period. The number and severity (0 = none, 
1 = mild, 2 = moderate, and 3 = severe) of hot flashes were 
recorded each day. Note that each hot flash was not given a 
severity rating, but rather the average severity rating for all the 
daily hot flashes was reported. The total number of hot flashes 
was simply the sum of the daily hot flashes over the   seven-day 
period. Mean severity was calculated as the mean of the daily 
severity ratings. A daily hot flash score was   calculated as 
the number of hot flashes times the average daily severity, 
and the mean hot flash score was calculated as the mean of 
the daily hot flash scores across the seven days. Participants 
had previously completed a diary for the closeout visit of the 
original study, and the vasomotor symptom data from that 
previous visit (calculated as described above) were added to 
the follow-up data file so that we could assess changes over 
time in vasomotor symptoms.
Means ± standard deviation (SD) and percentages were 
generated to describe the characteristics of the SEA follow-up 
participants. For race, black and other were combined, 
incomes were dichotomized above and below $45,000, edu-
cation was dichotomized as equal to or below high school 
or greater than high school, body mass index (BMI) was 
categorized into four groups based on the Centers for Disease 
Control criteria, underweight (BMI , 18.5 kg/m2), normal 
weight (BMI 18.5–25), overweight (BMI 25–30), obese 
class I ( BMI $ 30). The underweight and normal weight 
categories were combined for the analyses. Chi-squared tests 
and Kruskal–Wallis tests were used to assess the univariate 
associations between participant characteristics and soy/ 
hormonal therapy use. Logistic regression models were used 
to determine which characteristics (of those shown in Table 1) 
were jointly predictive of soy and hormonal therapy use and 
to determine which factors were associated with continued 
hot flashes. Linear regression on ranks was used to determine 
which factors were associated with the number of hot flashes 
and the hot flash score. Pearson correlation coefficients were 
used to assess the association between vasomotor symptoms 
of the SEA participants at closeout and vasomotor symptoms International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 1 Factors associated with soy and hormone therapy use among seA follow-up participants*
Characteristic Neither soy nor HT Soy only HT only Soy and HT P value
n (%) n (%) n (%) n (%)
Total 62 (100) 62 (100) 39 (100) 19 (100)
Age (years) 
  ,55 
  $55
 
33 (53) 
29 (47)
 
32 (52) 
30 (48)
 
17 (44) 
22 (56)
 
12 (63) 
7 (37)
0.555
race 
  White 
  Other
 
56 (92) 
5 (8)
 
54 (87) 
8 (13)
 
36 (92) 
3 ( 8)
 
16 (84) 
3 (16)
0.655
Income 
  ,$45,000 
  $$45,000
 
30 (52) 
28 (48)
 
23 (38) 
37 (62)
 
10 (26) 
29 (74)
 
6 (32) 
13 (68)
0.063
education 
  #High school 
  .High school
 
14 (23) 
47 (77)
 
12 (19) 
50 (81)
 
5 (13) 
34 (87)
 
5 (26) 
14 (74)
0.555
BMI 
  Underweight–normal 
  Overweight 
  Obese
 
24 (39) 
14 (23) 
24 (39)
 
24 (39) 
21 (34) 
17 (27)
 
21 (54) 
9 (23) 
9 (23)
 
13 (68) 
5 (26) 
1 (5)
0.057
general health 
  excellent 
  good 
  Fair–poor
 
18 (29) 
39 (63) 
5 (8)
 
21 (34) 
35 (56) 
6 (10)
 
16 (41) 
22 (56) 
1 (3)
 
8 (42) 
11 (58) 
0 (0)
0.553
Hysterectomy/oophorectomy 
  no 
  Yes
 
44 (71) 
18 (29)
 
42 (68) 
20 (32)
 
24 (62) 
15 (38)
 
11 (58) 
8 (42)
0.646
Medical conditions 
 0  
 1  
 2 +
 
31 (50) 
16 (26) 
15 (24)
 
31 (50) 
13 (21) 
18 (29)
 
16 (41) 
14 (36) 
9 (23)
 
11 (58) 
4 (21) 
4 (21)
0.719
Prescription medications 
 0  
 1  
 2  
 3 +
 
30 (48) 
13 (21) 
8 (13) 
11 (18)
 
24 (39) 
17 (27) 
10 (16) 
11 (18)
 
3 (8) 
11 (28) 
13 (33) 
12 (31)
 
1 (5) 
8 (42) 
3 (16) 
7 (37)
,0.001
Previous days with hot flashes/week** 
 0  
  1–6 
 7
 
9 (24) 
7 (18) 
22 (58)
 
12 (26) 
17 (37) 
17 (37)
 
11 (41) 
8 (30) 
8 (30)
 
3 (23) 
4 (31) 
6 (46)
0.240
Previous hot flashes/week*** 
Previous hot flash severity*** 
Previous hot flash score***
17.8 (14.8) 
1.06 (0.81) 
4.17 (4.16)
17.8 (26.8) 
0.88 (0.81) 
4.96 (10.5)
14.3 (18.4) 
0.74 (0.84) 
3.85 (5.85)
15.8 (18.7) 
0.93 (0.75) 
3.43 (4.18)
0.555 
0.348 
0.567
*not all patients had complete data; **previous refers to the closeout visit of the original seA study; ***mean (sD), n = 124 (38 no soy or HT, 46 soy only, 27 HT only,   
13 both soy and HT).
Abbreviations: BMI, body mass index; seA, soy and estrogen Alternative; HT, hormone therapy. 
at follow-up. Paired t-tests were used to assess the change 
in these symptoms.
Results
One hundred and eighty-two women provided survey data for 
this study, representing a response rate of 76%. Thirty-three 
survey packets were returned unopened, and all attempts 
to locate these women were unsuccessful. Twenty-five 
women declined the offer to participate and one woman 
was deceased.
Demographic characteristics for the 182 participants in 
this follow-up study are summarized by soy/hormonal ther-
apy use in Table 1. Overall, 81 (45%) of the 182 follow-up 
participants were using soy, including 58 for relief of hot 
flashes, two for relief of other menopausal symptoms, and 21 
for both. Mean age was 55 years and most women were white 
and had more than a high school education.   Ninety-three 
percent rated their health as good or excellent; with almost 
half of the women reporting that they had had no medical 
conditions in the past two years, and 68% responded that International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table  2  Hot  flashes  and  menopausal  symptoms  experienced  by  SEA  follow-up  participants  over  seven  consecutive  days  by   
soy/HT use
Characteristic Neither soy nor HT Soy only HT only Soy and HT P value
n (%) n (%) n (%) n (%)
Total 62 (100) 62 (100) 39 (100) 19 (100)
Days with hot flashes (n)  ,0.001
 0  
  1–6 
 7
24 (39) 
13 (21) 
25 (40)
16 (26) 
21 (34) 
25 (40)
30 (77) 
5 (13) 
4 (10)
10 (53) 
8 (42) 
1 (5)
Hot flashes (n) 
Hot flash severity (n) 
Hot flash score (n)
14.2 (17.6) 
0.84 (0.89) 
3.73 (5.64)
18.4 (25.9) 
1.01 (0.90) 
5.46 (10.6)
2.9 (8.0) 
0.24 (0.60) 
0.82 (2.40)
2.9 (4.8) 
0.35 (0.56) 
0.68 (1.31)
,0.001 
,0.001 
,0.001
number of menopausal symptoms 
  0–5 
  6–10 
  11–20 
  21+
 
16 (26) 
10 (16) 
22 (35) 
14 (23)
 
10 (16) 
11 (18) 
27 (44) 
14 (23)
 
5 (13) 
18 (46) 
13 (33) 
3 (8)
 
8 (42) 
3 (16) 
6 (32) 
2 (11)
0.006
Menopausal symptoms (n) 13.0 (8.3) 14.1 (7.4) 10.6 (6.1) 9.7 (7.9) 0.043
Abbreviations: seA, soy and estrogen Alternative; HT, hormone therapy; sD, standard deviation.
they were taking one or more prescribed medications. These 
characteristics were similar for women who did and did not 
use soy/hormonal therapy.
Forty-five percent of the women were using soy and 
32% were taking hormonal therapy. Those who were not 
using hormonal therapy were more likely to be using soy 
than those who were using hormonal therapy (50% versus 
33%, P = 0.03). Hormonal therapy use was the only factor 
significantly associated with soy use in the multivariable 
logistic model. Soy use (P = 0.013), number of prescrip-
tions (P = 0.003), and BMI (P = 0.037) were all significantly 
associated with hormonal therapy use in the logistic model. 
Women who were not taking soy, those with more prescrip-
tions, and those with lower BMIs were more likely to use 
hormonal therapy. One hundred and twenty-four of the 
182 women in the follow-up study had previously completed 
the original SEA study closeout visit. Seventy-two percent 
of those women were experiencing vasomotor symptoms 
at closeout, with a mean (SD) of 16.8 (20.9) symptoms 
per week. Those with vasomotor symptoms at the closeout 
visit were no more likely to be using soy or hormonal therapy 
at the follow-up visit than those who did not have vasomotor 
symptoms, unadjusted or adjusted for other factors.
Vasomotor symptoms recorded in the follow-up diaries 
are summarized in Table 2. Eighty women (44%) did not 
experience hot flashes during the week they completed the 
diary, 55 (30%) experienced at least one hot flash every day of 
the week, while the remaining 47 women (26%) experienced 
hot flashes on 1–6 days. Thirty-three women (18%) reported 
1–7 hot flashes during the week, and 29 (16%) reported 29 or 
more hot flashes. One participant experienced 164 hot flashes 
for the week. Women with lower incomes (P = 0.040) and 
those who did not use hormonal therapy (P , 0.001) were 
more likely to report having hot flashes.
The mean number of hot flashes was 12.0 (19.7) and 
was significantly lower for those using hormonal therapy 
(2.9   versus 16.3, P , 0.001). No hot flashes were reported 
on 57% of the days for which diaries were kept, 1–5 were 
reported for 33% of the days, 6–9 for 8%, and $10 for 2% 
of the days. The daily hot flashes were typically mild to 
moderate. Only 12% of the days were recorded as severe. 
The mean hot flash score was 3.4 (7.3) and was significantly 
lower for those using hormonal therapy (0.77 versus 4.59, 
P , 0.001).
Women who were experiencing hot flashes at the close-
out visit of the original SEA study were more likely to have 
experienced them during the follow-up survey; 14 (40%) of 
35 women who reported no hot flashes at closeout reported 
them at follow-up compared with 57 (64%) of 89 women 
who reported hot flashes at closeout (P = 0.01). Amongst the 
124 women with vasomotor symptom data at closeout and 
follow-up, the number of weekly hot flashes dropped by a 
mean of 3.9 (P = 0.03) and the hot flash score decreased by 
0.7 points (P = 0.17). The number of hot flashes at closeout 
was significantly correlated with the number at follow-up 
(r = 0.58, P , 0.001), as were the hot flash scores at closeout 
and follow-up (r = 0.71, P , 0.001). In the multivariable 
linear models, only hormonal therapy and number of prior 
hot flashes were significantly associated with number of hot 
flashes or the hot flash score.
The number of menopausal and physical symptoms 
experienced by participants during the four weeks prior to International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
385
soy estrogen Alternative follow-up
the follow-up survey was also evaluated. All but six women 
experienced at least one symptom, and the median number 
of symptoms experienced was 12. Joint pain and stiffness, 
general aches and pains, fatigue, bloating, and hot flashes 
were the most common symptoms, each occurring in more 
than 60% of the participants.
Women also reported their use of herbal supplements for 
menopausal symptoms. Thirty-five women (19%) reported 
that they used herbal products for hot flashes. The most 
common herbal product taken for hot flashes was black 
cohosh (19 women). Twenty-eight women (15%) reported 
using herbal products for other symptoms of menopause. 
The most common herbal products used for other symptoms 
were black cohosh and ginkgo biloba, both of which were 
taken by 10 women.
Discussion
An estimated two million American women are transition-
ing through menopause each year and are actively seeking 
therapies to treat their menopausal symptoms.7 This follow-
up study was conducted to evaluate women who, when hor-
monal therapy was widely prescribed for vasomotor symptom 
management, opted to seek an alternative treatment for their 
menopausal symptoms by participating in the SEA study. 
Querying these participants a few years after the completion 
of the SEA study allowed for a longer-term evaluation of their 
menopausal symptoms and soy product consumption.
Women reporting having at least one vasomotor symptom 
over a 24-hour period met the eligibility criteria to participate 
in the SEA study. Of the 182 participants surveyed, more than 
half were still experiencing hot flashes, with 30% having at 
least one every day of the week and 26% experiencing hot 
flashes on 1–6 days. Fifty-eight women were using hormonal 
therapy, and these women were experiencing fewer and less 
severe hot flashes. While hormonal therapy is effective in 
treating hot flashes, it is less effective in treating the other 
menopausal symptoms reported, including joint pain and 
stiffness, general aches and pains, fatigue, and bloating, and 
hormonal therapy has known deleterious health effects. This 
emphasizes the critical need for more research to identify and 
test longer-term treatments for menopausal symptoms.
An interesting finding was that half the women who 
were not taking HT and were still experiencing the most hot 
flashes, and those not taking hormonal therapy were using 
soy. There was no significant difference in hot flash frequency 
or severity between those who were and were not taking 
soy. In the original SEA study, each group had a significant 
decline in hot flash frequency and severity, even though 
the declines did not differ significantly by isoflavone dose. 
Although the isoflavones were not found to be responsible 
for reducing vasomotor symptoms in the SEA study, other 
components of soy may be responsible for the reduction of 
vasomotor symptoms. This seems plausible because 43% of 
the women reported that they continued to consume soy to 
treat their hot flashes (perhaps fearing that their symptoms 
might worsen if they stopped taking soy).
This study has some limitations that should be acknowl-
edged. The data were collected from women who had 
participated in a soy intervention study and therefore were 
likely to be high utilizers of complementary and alterna-
tive therapies, and may be different from other menopausal 
women. However, with the highly publicized findings regard-
ing hormonal therapy from the Women’s Health Initiative 
Trial, more women experiencing symptoms of menopause 
are investigating alternative therapies with “lower” risk 
profiles to treat their hot flashes.8 Additionally, the literature 
supports the contention that women are using complementary 
and alternative medicine products for menopausal symptom 
management. Another limitation is that the data were self-
reported.
Conclusion
This study adds to the current literature by evaluating vasomo-
tor and other menopausal symptoms and soy/hormonal therapy 
use in a group of women who participated in a clinical trial 
testing an alternative therapy for vasomotor symptom manage-
ment. We report that most of the women continued to experi-
ence menopausal symptoms, some for over four years, and 
currently no optimal treatments exist to provide these women 
with long-term symptom relief. Many of the most symptomatic 
women continued to use soy for menopausal symptom relief, 
even though they were aware of the SEA study results. Given 
the publications regarding the risks associated with hormonal 
therapy, greater numbers of menopausal women are seeking 
alternative therapies, and efforts to identify and test approaches 
for vasomotor symptom relief are warranted.
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